Halozyme Therapeutics Accounts Receivables 2011-2026 | HALO

Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.

Examples of accounts receivable

Customers have not paid invoices for delivered products
An advance has been paid to a supplier, but goods have not yet been received
Employees have not reported on accountable amounts
The government must refund tax overpayments
Outstanding loans issued

Importance of accounts receivable in company analysis

Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment.
Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages.
Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)

Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)

If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.

Annual Accounts Receivables Halozyme Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
426 M	288 M	233 M	231 M	-	97.7 M	59.4 M	30 M	22.1 M	15.7 M	32.4 M	9.15 M	9.1 M	15.7 M	2.26 M	2.33 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
426 M	2.26 M	98.3 M

Quarterly Accounts Receivables Halozyme Therapeutics

2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
458 M	344 M	315 M	304 M	288 M	273 M	210 M	185 M	233 M	214 M	222 M	195 M	187 M	233 M	189 M	114 M	91 M	112 M	153 M	88.4 M	97.7 M	97.7 M	97.7 M	97.7 M	59.4 M	59.4 M	59.4 M	59.4 M	30 M	30 M	30 M	30 M	22.1 M	22.1 M	22.1 M	22.1 M	15.7 M	15.7 M	15.7 M	15.7 M	32.4 M	32.4 M	32.4 M	32.4 M	9.15 M	9.15 M	9.15 M	9.15 M	9.1 M	9.1 M	9.1 M	9.1 M	15.7 M	15.7 M	15.7 M	15.7 M	2.26 M	2.26 M	2.26 M	2.26 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
458 M	2.26 M	93.1 M

Accounts Receivables of other stocks in the Biotechnology industry

Issuer	Accounts Receivables	Price	% 24h	Market Cap	Country
FSD Pharma HUGE	73.6 K	-	5743.5 %	$ 69.7 M	Canada
Happiness Biotech Group Limited HAPP	11.4 K	-	1.35 %	$ 17.8 M	China
AgeX Therapeutics AGE	57 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	130 M	-	-	$ 866 M	China
Esperion Therapeutics ESPR	140 M	$ 3.14	0.16 %	$ 653 M	USA
Eton Pharmaceuticals ETON	11.8 M	$ 34.42	4.65 %	$ 926 M	USA
Berkeley Lights BLI	18.5 M	-	-7.31 %	$ 87 M	USA
Arcturus Therapeutics Holdings ARCT	5.56 M	$ 6.84	2.17 %	$ 187 M	Israel
Generation Bio Co. GBIO	1.22 M	-	-	$ 344 M	USA
Autolus Therapeutics plc AUTL	24 M	$ 1.64	0.61 %	$ 436 M	Britain
Ayala Pharmaceuticals AYLA	234 K	-	-	$ 7.46 M	Israel
Heron Therapeutics HRTX	89.6 M	$ 0.85	0.57 %	$ 142 M	USA
Compugen Ltd. CGEN	61 M	$ 2.74	0.18 %	$ 256 M	Israel
Anika Therapeutics ANIK	23.7 M	$ 15.15	2.23 %	$ 217 M	USA
Advaxis ADXS	234 K	-	-9.65 %	$ 45.9 M	USA
Applied Genetic Technologies Corporation AGTC	1.7 M	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	200 K	-	1.93 %	$ 17.4 M	USA
Aptinyx APTX	257 K	-	-39.0 %	$ 4.57 M	USA
Coherus BioSciences CHRS	17.8 M	$ 1.52	2.7 %	$ 178 M	USA
Albireo Pharma ALBO	3.27 M	-	-0.23 %	$ 916 M	USA
Arcutis Biotherapeutics ARQT	146 M	$ 20.45	4.9 %	$ 2.6 B	USA